Illumina, Inc. $ILMN Stock Holdings Lessened by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 279,164 shares of the life sciences company’s stock after selling 16,433 shares during the period. Stephens Investment Management Group LLC’s holdings in Illumina were worth $26,635,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of ILMN. Rise Advisors LLC raised its stake in Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 224 shares during the period. Cullen Frost Bankers Inc. acquired a new stake in Illumina during the 2nd quarter valued at $41,000. Golden State Wealth Management LLC raised its stake in Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 292 shares during the period. Caitong International Asset Management Co. Ltd raised its stake in Illumina by 2,936.8% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 577 shares of the life sciences company’s stock valued at $46,000 after purchasing an additional 558 shares during the period. Finally, WPG Advisers LLC acquired a new stake in Illumina during the 1st quarter valued at $58,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research analyst reports. Royal Bank Of Canada set a $124.00 price target on shares of Illumina in a report on Tuesday, September 2nd. Robert W. Baird boosted their price target on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a report on Monday, July 28th. Citigroup cut shares of Illumina from a “hold” rating to a “strong sell” rating and lowered their price target for the company from $85.00 to $80.00 in a report on Wednesday, July 9th. Wall Street Zen cut shares of Illumina from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Finally, Canaccord Genuity Group upped their price objective on shares of Illumina from $99.00 to $105.00 and gave the stock a “hold” rating in a report on Friday, August 1st. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $115.25.

Illumina Stock Down 1.7%

ILMN stock opened at $97.23 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a 50-day moving average of $98.17 and a two-hundred day moving average of $91.11. The stock has a market capitalization of $14.94 billion, a price-to-earnings ratio of 12.31, a price-to-earnings-growth ratio of 2.44 and a beta of 1.40.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.